Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rafael G Mendez"'
Autor:
Vladimir Burilov, Rustem Zairov, Julia Elistratova, Rafael G. Mendez, Alexey Stepanov, Marsil K. Kadirov, Elena A. Zvereva, Svetlana S. Lukashenko, Irek R. Nizameev, Rustem Amirov, Mark H. Rümmeli, Sergey A. Katsuba, Marina Pinus, Asiya R. Mustafina
Publikováno v:
Colloids and Surfaces A: Physicochemical and Engineering Aspects. 443:450-458
The article introduces transverse relaxation rates of water protons in the aqueous hydrophilic colloids synthesized on the basis of the oleate-coated iron oxide nanoparticles (17 nm) with non-ionic and cationic surfactants, triblock copolymers, polye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53230de593e6008400edf006b6c40f73
https://doi.org/10.1016/j.colsurfa.2013.12.009
https://doi.org/10.1016/j.colsurfa.2013.12.009
Autor:
Rocio Gonzalez, Pietro Dentico, Katia Schlienger, Jon E. Stek, Andrew S. Robertson, Christina Y. Chan, Jeffrey G. Smith, Ira Chalikonda, Rupert Vessey, Clemente Diaz, Jeffrey L. Silber, William Wang, Florian Schödel, Holly Matthews, Jerald C. Sadoff, Rafael G Mendez, Michael J. Caulfield, Luigi Roberto Biasio, Ivan S. F. Chan, Julie L Barben, Anna L. Harmon, Sandro Cinquetti
Publikováno v:
Vaccine. 24(47-48)
A new manufacturing process, known as process upgrade varicella vaccine (PUVV) was developed for a refrigerated formulation of varicella vaccine and for an investigational zoster vaccine. Safety and tolerability of a two-dose regimen of high-titered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e2adba95e733738ebbad3811751ec51
https://pubmed.ncbi.nlm.nih.gov/17050042
https://pubmed.ncbi.nlm.nih.gov/17050042
Autor:
Mark S. Soloway, Armand Bouzaglou, Virginia L. Naessig, Alun L. Yakabow, Daniel Eventov, Melody R. Wyres, Barton Tanenbaum, Sol S. Klioze, Rafael G. Mendez, Seth N. Presant, Barbara Todd, Cary A. Presant, Charles L. Wiseman, Peter S. Kennedy
Publikováno v:
Cancer. 59:1713-1716
The safety and efficacy of buserelin, a luteinizing hormone-releasing hormone (LH-RH) agonist, was tested in 33 evaluable patients with Stages C or D adenocarcinoma of the prostate. With a minimum follow-up duration of 10 months, there was one comple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce9ebbf79d077ae7f15061e81f95cee2
https://doi.org/10.1002/1097-0142(19870515)59:10<1713::aid-cncr2820591006>3.0.co
https://doi.org/10.1002/1097-0142(19870515)59:10<1713::aid-cncr2820591006>3.0.co
Autor:
Armand Bouzaglou, Peter S. Kennedy, Virginia L. Naessig, Melody R. Wyres, Daniel Eventov, Mark S. Soloway, Kimball S. Ford, John W. Kosola, Charles L. Wiseman, Sol S. Klioze, Alun L. Yakabow, Rafael G. Mendez, Barton Tanenbaum, Cary A. Presant
Publikováno v:
Cancer. 56:2416-2419
The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1f1b867dc8ce31571c2aee13786a1bc
https://doi.org/10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co
https://doi.org/10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co